Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Utility of the Apoptosis Imaging Biomarker 18F]ML10 in Patients With Non-Hodgkin's Lymphoma(NHL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Capable of giving written informed consent, and willing and able to comply with the requirements and restrictions listed in the consent form.~2. Male or female patients \>18 years of age at screening with histological or cytological diagnosis of Non-Hodgkin's Lymphoma and due to receive intravenous chemotherapy for the first time~3. A female subject is eligible to participate if she has non-childbearing potential~4. Male subject must agree to use one of the contraception methods listed~5. Able to lie comfortably on back for up to 70 minutes at a time.~6. WHO performance status 0, 1 or 2 -~Exclusion Criteria:~1. Patients with known history of Hepatitis B, C, non-A, non-B and HIV~2. Any clinically significant medical conditions that in the opinion of the investigator would compromise the compliance with study procedures.~3. Pregnant or breast feeding females.~4. Any other prior anticancer therapy~5. Any new investigational agent, including an investigational anti-cancer agent~6. History of sensitivity to heparin or heparin-induced thrombocytopenia.~7. Males and females not able to comply with contraceptive guidelines during the study.~   -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- no treatment (Type: NO_INTERVENTION): no treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).